Description
A triple monoamine reuptake inhibitor developed by Hoffman-LaRoche in the 1970s as an antidepressant but discontinued, probably due to high abuse potential. Has not become popular as a recreational drug at this time. Acts as an SNDRI, mostly inhibits dopamine and noradrenaline.
Effects & Dosing
Dosage
Oral
| Threshold | Light | Common | Strong | Heavy |
|---|---|---|---|---|
| 12-15 mg | 30-40 mg | 40-60 mg | - | 60-80 mg |
Duration
Oral
Total Duration 4h - 6h
Safety & Risks
Safer Use
- NOTE: These doses are tentative and may need further research.
Everything in OpenMind
Track your use, check combinations and find safer use tips – even offline.